DB
LKFT

Dmitry Balyasny’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Dmitry Balyasny’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,000
Closed -$1.38M – 2604
2021
Q4 		$1.38M Buy
+25,000
New +$1.3M ﹤0.01% 1365

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Dmitry Balyasny's LKFT Position: Q4 2022 in Review

Dmitry Balyasny sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 8,147 shares — an estimated $347K sold.

Dmitry Balyasny first reported a position in LKFT in Q4 2020 and held it in 4 quarters. The position peaked at $5.25M in Q1 2021. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

  • Dmitry Balyasny reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 8,147 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $347K.
  • Dmitry Balyasny first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 4 quarters.
  • Dmitry Balyasny's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.25M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.